$4.38
10.25% today
Nasdaq, Apr 04, 09:16 pm CET
ISIN
US98422L1070
Symbol
XERS
Sector
Industry

Xeris Pharmaceuticals Inc Stock price

$4.88
+1.19 32.25% 1M
+1.90 63.76% 6M
+1.49 43.95% YTD
+2.80 134.62% 1Y
+2.24 84.85% 3Y
+3.19 187.91% 5Y
-15.34 75.87% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.27 5.24%
ISIN
US98422L1070
Symbol
XERS
Sector
Industry

Key metrics

Market capitalization $751.23m
Enterprise Value $951.06m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.68
P/S ratio (TTM) P/S ratio 3.70
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 23.89%
Revenue (TTM) Revenue $203.07m
EBIT (operating result TTM) EBIT $-33.65m
Free Cash Flow (TTM) Free Cash Flow $-37.85m
Cash position $71.62m
EPS (TTM) EPS $-0.38
P/E forward negative
P/S forward 2.86
EV/Sales forward 3.63
Short interest 7.46%
Show more

Is Xeris Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Xeris Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Xeris Pharmaceuticals Inc forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Xeris Pharmaceuticals Inc forecast:

Buy
83%
Hold
17%

Financial data from Xeris Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
203 203
24% 24%
100%
- Direct Costs 48 48
21% 21%
23%
155 155
25% 25%
77%
- Selling and Administrative Expenses 151 151
13% 13%
74%
- Research and Development Expense 26 26
14% 14%
13%
-21 -21
32% 32%
-10%
- Depreciation and Amortization 13 13
4% 4%
6%
EBIT (Operating Income) EBIT -34 -34
24% 24%
-17%
Net Profit -55 -55
12% 12%
-27%

In millions USD.

Don't miss a Thing! We will send you all news about Xeris Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xeris Pharmaceuticals Inc Stock News

Neutral
Business Wire
7 days ago
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced changes to its board of directors. Ricki Fairley has resigned from the board in light of other commitments, effective immediately. The Board of ...
Neutral
Business Wire
18 days ago
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that its supplemental new drug application (sNDA) of Gvoke VialDx™ has received U.S Food and Drug Administration (FDA) approval ...
Neutral
Seeking Alpha
29 days ago
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve Pieper - CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Oren Livnat - H.C. Wainwright Glen Santangelo - Jefferies David Amsellem - Piper Sandler Leland Gershell - Oppenheimer M...
More Xeris Pharmaceuticals Inc News

Company Profile

Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL.

Head office United States
CEO John Shannon
Employees 394
Founded 2005
Website www.xerispharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today